iC9-CAR.B7-H3 T cells

iC9-CAR.B7-H3 T cells are an investigational chimeric antigen receptor (CAR) T cell therapy engineered to target the B7-H3 antigen, which is overexpressed in various solid tumors. These autologous (patient-derived) T cells are genetically modified to express a CAR specific for B7-H3 and incorporate an inducible caspase 9 (iC9) safety switch. The iC9 system allows for rapid elimination of the infused CAR-T cells upon administration of a small molecule dimerizer (such as rimiducid or AP1903), providing a safety mechanism in case of severe adverse events. The primary indications under investigation include relapsed or refractory platinum-resistant epithelial ovarian cancer, triple negative breast cancer, pancreatic ductal adenocarcinoma, and uveal melanoma liver metastases. Preclinical studies have shown robust antitumor activity and effective eradication of tumor models; clinical trials are ongoing to assess safety and efficacy[1][2][4][5][8].

Other names

autologous anti-B7-H3 CAR-iC9-expressing T lymphocytesB7-H3-targeted CAR-T with inducible caspase 9 suicide switchB-7-H3-targeted CAR-T with inducible caspase 9 suicide switchB 7-H3-targeted CAR-T with inducible caspase 9 suicide switch